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Abstract
Background: There is increasing evidence that attitudes and beliefs are important in predicting
adherence in depressive and bipolar disorders. However, such attitudes and beliefs on mood
stabilizers have not been analysed by socio-demographic and clinical variables.
Methods: The Mood Stabilizer Compliance Questionnaire (MSQC) was mailed to a large
population of patients with depressive or bipolar disorder representative of patients treated at
their first contacts to hospital settings in Denmark.
Results: Of the 1005 recipients, 49.9 % responded to the letter and among these 256 indicated
that they previously had been or currently were in treatment with a mood stabilizer. A large
proportion of the patients (40 to 80 %) had non-correct views on the effect of mood stabilizers.
Older patients consistently had a more negative view on the doctor-patient relationship, more non-
correct views on the effect of mood stabilizers and a more negative view on mood stabilizers.
There was no difference in the attitudes and beliefs according to the type of disorder (depressive
or bipolar), the number of psychiatric hospitalisations or according to the type of the current
doctor (general practitioner, private psychiatrist, community psychiatry doctor, hospital doctor,
other doctor).
Conclusion: There is a need of improving knowledge and attitudes toward diagnosis and
treatment especially among elder patients as this may add to improve the prognosis of depressive
and bipolar disorders.
1. Introduction
Medication non-adherence for depressive and bipolar dis-
orders range from 10 to 60 % (median 40 %). It has
recently been concluded in a review [1] that it seems as
attitudes and beliefs are at least as important as side-
effects in predicting adherence in depressive and bipolar
disorders [2-4]. Beliefs and expectations has in several
studies been found to be associated with non-adherence
to lithium [1,5,6] and a recent study similarly concluded
that attitudes and behaviours are better predictors of non-
adherence to mood stabilizers than side effects of medica-
tion [7]. Nevertheless, most of the studies have included a
rather small number of patients [5,8-11] which might
explain the very few attempts that have been made to cor-
relate attitudes and beliefs with gender and age or with
diagnostic subtypes (unipolar versus bipolar disorder)
[12].
Demyttenaere et al [13] have recently developed a ques-
tionnaire (The Antidepressants Compliance Question-
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concerning depression and antidepressive treatment. Fac-
tor analysis identified four meaningful components [13]
and the test-retest reliability of the ADQC was found
acceptable [13]. We have developed a questionnaire ana-
logue to the ADQC to measure attitudes and beliefs con-
cerning depressive and/or manic episodes and treatment
with mood stabilizers, the Mood Stabilizer Compliance
Questionnaire (MSCQ). We have thus replaced all the
items concerning antidepressants with mood stabilizers
and replaced items concerning depressive episodes with
depressive and/or manic episodes. Apart from these
adjustments no other changes have been made. Hence,
the scoring of the items in the MSCQ is identical to the
ADQC.
The objectives of the present study were (a) to characterise
attitudes and beliefs on diagnosis and treatment with
mood stabilizers by means of the MSQC among patients
with severe depressive and bipolar disorders treated at
their first contacts to hospital psychiatry and (b) to ana-
lyse the results in relation to socio-demographic and clin-
ical variables. Thus, we have investigated the score on the
MSQC in relation to age and gender and tested whether
the score was different for patients with depressive disor-
der and patients with bipolar disorder and whether the
score was related to the number of severe affective epi-
sodes patients had experienced.
2. Methods
2.1. The register
The Danish Psychiatric Central Research Register
(DPCRR) is nation-wide with registration of all psychiat-
ric hospitalisations in Denmark for the 5.3 million inhab-
itants [14]. From January 1, 1995 the register included
information on patients in psychiatric ambulatories and
community psychiatric centres, also.
All inhabitants in Denmark have a unique person identi-
fication number (Civil Person Registration number, CPR-
number) that can be logically checked for errors; so it can
be established with great certainty if a patient has had con-
tact to psychiatric service previously, irrespective of
changes in name etc. The International Classification of
Diseases, 10th Revision [15] has been used in Denmark
from January 1, 1994.
2.2. The sample
A total sample of 1005 patients with address in Denmark
was identified as follows by means of the Danish Psychi-
atric Central Research Register:
1. A random sample including 25 % of all patients who in
2002, at their first discharge ever from a psychiatric hospi-
tal, had received the diagnosis of single or recurrent
depression (ICD-10, DF32-33). N = 311.
2. All patients who in 2002, at their third discharge ever
from a psychiatric hospital, had received a diagnosis of
recurrent depression (ICD-10, DF33). N = 213.
3. All patients who in 2002, at their first discharge ever from
a psychiatric hospital, had received a diagnosis of mania/
bipolar affective disorder (ICD-10, DF30-31). N = 181.
4. All patients who in 2002, at their third discharge ever
from psychiatric hospital, had received a diagnosis of
bipolar affective disorder (ICD-10, DF31). N = 195.
5. All patients who in 2001 or 2002, at their first outpatient
visit ever to a psychiatric ambulatory or community-psy-
chiatric centre, had received a diagnosis of mania/bipolar
affective disorder (ICD-10, DF30-31). N = 105.
Patients were included in this way to get a greater varia-
tion in the number of admissions.
2.3. The Mood Stabilizer Compliance Questionnaire
(MSQC)
The Mood Stabilizer Compliance Questionnaire (MSQC)
is developed as an analogue questionnaire to the Antide-
pressant Compliance Questionnaire (ADCQ) by Demyt-
tenaere [13] with 33 analogue questions.
MSQC consists of 33 items that are scored as follows: 1
(mostly disagree), 2 (rather disagree), 3 (rather agree) and
4 (mostly agree) [13]. Mean values (SD) were calculated
according to the ADCQ scoring system from 1 to 4 by
Demyttenaere [13]. The higher the score, the more posi-
tive the patients beliefs and attitudes toward compliance
are. The 33 items were subdivided into four components
of items: component 1 (perceived doctor-patient relation-
ship, items 2, 5, 7, 12, 14, 15, 16, 19, 20, 21, 22, 25, 27,
28, 29), component 2 (beliefs on mood stabilizers, items
4, 10, 11, 17, 18, 32, 33), component 3 (preserved auton-
omy in general, items 1, 3, 6, 9, 13, 24) and component 4
(preserved autonomy in dosing of mood stabilizers, items
8, 23, 26, 30) in a way nearly similar to the ADCQ [13].
The MSQC was mailed to patients as part of a larger survey
during spring 2004. The study was carried out in compli-
ance with the Helsinki Declaration. The local ethical com-
mittee approved the study (KF 01-159/02) allowing
mailing of one reminder only if patients did not respond
to the initial letter.Page 2 of 7
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In univariate analyses, categorical data were analysed with
chi-square test (2-sided) and continuous data were ana-
lysed with the Mann-Whitney test for two independent
groups. In multiple regression analyses, component 1, 2,
3, 4 of the MSQC were included as outcome, respectively,
and gender, age at first contact, number of admissions and
type of disorder (depressive versus bipolar disorder) were
included as predictive variables.
P < 0.05 was used to indicate statistical significance. SPSS
software package for windows, version 11.0 was used
[16].
3. Results
Among the 1005 patients who were identified in the reg-
ister with a diagnosis of depressive disorder or mania/
bipolar disorder, 16 patients were excluded (7 due to
unknown address, 6 as the patients did not understand
Danish, 2 as the patients according to relatives were to
demented and 1 as the patient has died). Among the
remaining 989 patients who were potentially able to
respond to the questionnaires, 493 patients fulfilled the
questionnaires, corresponding to a response rate of 49.9
%. Among the 493 patients who fulfilled the question-
naires, 256 (51.9 %) responded that they previously or
currently were in treatment with a mood stabilizer.
Totally, 108 patients indicated that they currently were
taking lithium, 10 patients were taking carbamazepine, 14
patient valproate and 35 patients were currently taking
lamotrigene. Among these patients, 7 patients got combi-
nations of various kinds of mood stabilizers. We did not
ask for the type of the prior mood stabilizers, as such data
may be inaccurate. As can be seen from Table 1, signifi-
cantly more women (53.4 %) than men (45.2 %)
responded to the overall questionnaires (p = 0.006). No
significant age differences at first discharge were seen
between the patients with depressive and those with bipo-
lar disorder or between the numbers of admissions in
responders versus non-responders to the questionnaire.
The responses to the 33 items of the MSQC are presented
in Table 2 for the 256 patients who reported that they pre-
viously or currently were in treatment with a mood stabi-
lizer. Mean (SD) values for each item are presented for
patients with depressive and bipolar disorder, separately
(also for comparison with future studies). Mean values
were calculated according to the scoring system from 1 to
4 by Demyttenaere [13]. The higher the score, the more
positive the patients beliefs and attitudes toward compli-
ance are. There were statistical differences in the scores
between depressive and bipolar disorder in four items
(items 4, 5, 18 and 24).
In general, the major proportion of patients agreed on the
diagnosis and the choice and effect of pharmacological
treatment and the majority felt content with their doctor
and with information regarding diagnosis and treatment.
Only minorities of patients had wrong ideas about dosing
or the effect of mood stabilizers (You may take fewer tab-
lets than prescribed on days when you feel better (8.1 %,
item 8). If you forget to take the mood stabilizer on a cer-
tain day, it is better to take an additional dose the follow-
ing day (10.6 %, item 23). You may take more tablets than
prescribed on days when you feel more depressed (6.6 %,
item 26). Skipping a day now and again prevents your
body from becoming immune to the mood stabilizers
(3.4 %, item 30)).
In contrast, a large proportion of the patients had non-
correct views on the effect of mood stabilizers
(Component2 (Preserved autonomy)). A total of 77.4 %
of the sample of patients agreed on item 1 that as long as
you are taking mood stabilizers you do not really know if
they are actually necessary. Accordingly, 50.0 % agreed on
item 3 that when you have taken mood stabilizers over a
long period of time it is difficult to stop taking them and
37.3 % agreed on item 6 that when you take mood stabi-
lizers you have less control over your thoughts and feel-
ings. Further, 41.7 % agreed that mood stabilizers can
alter your personality (item 9) and 49.8 % that your body
can become addicted to mood stabilizers (item 13) and
accordingly 36.1 % agreed that your body can become
immune to mood stabilizers (item 24). A total of 61.0 %
agreed that their depression and/or manic episodes are
mainly due to factors associated with their personality
(item 31).
Table 1: Socio-demographic and clinical characteristics of responders and non-responders to the questionnaires.
Responders N = 493 Non-responders N = 496 P
Age (median (quartiles)) 43.8 (33.3–53.4) 45.5 (33.5–55.8) 0.2
Men (%) 194 (45.2) 235 (54.8) 0.006
Women (%) 299 (53.4) 261 (46.6)
Depressive disorder (%) 258 (50.0) 258 (50.0) 0.9
Bipolar disorder (%) 235 (49.7) 238 (50.3)
Number of admissions (SD) 2.44 (2.24) 2.38 (1.42) 0.8Page 3 of 7
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1 As long as you are taking mood stabilizers you do not really know 
if they are actually necessary
11.5 11.1 23.8 53.0 1.82 (1.02) 2.00 (1.16)
2 My doctor listens properly to what I think about mood stabilizers 5.9 7.1 30.3 56.7 1.52 (0.95) 1.53 (0.80)
3 When you have taken mood stabilizers over a long period of time 
it is difficult to stop taking them
31.0 19.0 22.7 27.3 2.64 (1.14) 2.69 (1.14)
4 With mood stabilizers my depressions and/or manic episodes 
disappear
15.3 12.5 40.3 31.9 2.57 (1.15) 1.88 (0.85)*
5 My doctor has made me feel confident that mood stabilizers are 
the suitable treatment for me
9.5 8.7 28.1 53.7 1.93 (1.11) 1.59 (0.90)*
6 When you take mood stabilizers you have less control over your 
thoughts and feelings
43.9 18.9 21.3 16.0 3.09 (1.05) 2.98 (1.08)
7 My doctor takes sufficient time to listen to my problems 7.3 6.1 25.7 60.8 1.57 (0.97) 1.48 (0.69)
8 You may take fewer tablets than prescribed on days when you feel 
better
86.2 5.7 4.5 3.6 3.77 (0.71) 3.79 (0.61)
9 Mood stabilizers can alter your personality 39.3 19.0 24.0 17.8 2.82 (1.17) 2.90 (1.09)
10 My partner agrees that mood stabilizers are a suitable treatment 
for my condition
7.1 5.9 25.4 61.5 1.75 (0.97) 1.45 (0.79)
11 Mood stabilizers correct the changes that occurred in my brain 
due to stress or problems
13.7 14.9 34.9 36.5 2.20 (1.05) 1.95 (1.08)
12 My doctor has explained the causes of my disorder sufficiently 18.9 12.9 24.9 43.3 2.00 (1.18) 1.96 (1.11)
13 Your body can become addicted to mood stabilizers 30.8 19.4 16.9 32.9 2.50 (1.29) 2.61 (1.16)
14 My doctor takes sufficient time to discuss my emotional problems 8.7 12.4 26.6 52.3 1.61 (0.92) 1.76 (0.93)
15 My doctor has explained depression and mania sufficiently to me 12.9 11.2 25.8 50.2 1.89 (1.19) 1.81 (1.01)
16 My doctor shows sufficient consideration for my views and 
feelings about his treatment with mood stabilizers
8.8 7.1 30.8 53.3 1.82 (1.11) 1.64 (0.85)
17 Mood stabilizers help me to worry less about my problems 13.4 15.9 33.7 37.0 2.11 (0.95) 2.10 (1.086)
18 My partner agrees that depressive disorder or bipolar disorder is 
the correct diagnosis of my condition
16.0 8.9 21.9 53.3 2.34 (1.29) 1.60 (0.89)*
19 I receive sufficient psychological support and encouragement from 
my doctor
9.2 10.0 28.9 51.9 1.64 (0.97) 1.66 (0.84)
20 My doctor fully understands my condition 7.4 10.3 21.9 60.3 1.55 (0.975) 1.69 (0.92)
21 My doctor strongly emphasises that it is important to take the 
mood stabilizers regularly
5.7 3.7 20.5 70.1 1.52 (0.98) 1.35 (0.77)
22 My doctor is really interested in my problems 6.6 7.5 22.8 63.1 1.50 (1.00) 1.51 (0.83)
23 If you forget to take the mood stabilizer on a certain day, it is 
better to take an additional dose the following day
81.6 7.8 6.5 4.1 3.75 (0.69) 3.64 (0.82)
24 Your body can become immune to mood stabilizers 42.3 21.6 19.4 16.7 2.64 (1.16) 3.05 (1.08)*
25 My doctor listens properly when I tell him what it is like to be 
depressed
9.2 10.5 28.5 51.8 1.70 (1.05) 1.70 (0.88)
26 You may take more tablets than prescribed on days when you feel 
more depressed
87.1 6.2 2.5 4.1 3.80 (0.55) 3.85 (0.51)
27 My doctor understands my feelings and thoughts in depression 
and mania perfectly
11.3 11.8 30.7 46.2 1.66 (1.01) 1.88 (0.96)
28 My doctor has explained properly about mood stabilizers, their 
action and side effects
11.5 11.1 28.0 49.4 1.82 (1.04) 1.75 (1.01)
29 My doctor listens properly to what I consider to be the causes of 
my depression and/or manias
10.1 8.8 32.5 48.7 1.70 (1.00) 1.78 (0.93)
30 Skipping a day now and again prevents your body from becoming 
immune to the mood stabilizers
87.5 9.2 2.1 1.3 3.84 (0.53) 3.83 (0.47)
31 I think my depression and/or manic episodes are mainly due to 
factors associated with my personality
20.3 18.6 34.2 26.8 2.36 (1.14) 2.23 (1.06)
32 My emotional problems are solved by the mood stabilizers 27.5 24.2 30.8 17.5 2.77 (1.05) 2.61 (1.10)
33 Mood stabilizers make me stronger so I will be able to deal more 
efficiently with my problems
12.8 12.8 39.5 35.0 2.11 (1.02) 1.91 (0.98)
* In items 4, 5, 18 and 24 there are statistically significant differences between depressive and bipolar disorder (P ≤ 0.05). For all other items P > 
0.05 in comparisons of depressive and bipolar disorder.
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with component 1, 2, 3, 4 as outcome, respectively, and
with inclusion of gender, age at first contact, number of
admissions and type of disorder (depressive versus bipo-
lar disorder) as predictive variables. As can be seen, age at
first contact was negatively associated with all four com-
ponents (higher age associated with lower score), how-
ever not significantly with component 4 (B = -0.003, p =
0.2). There were no significant associations between any
component and gender, number of admissions or type of
disorder (depressive disorder versus bipolar disorder).
Including further a variable of educational level (dichot-
omised as primary school versus high school) did not
change the results substantially, although age only was
marginally associated with component 3 in this model (B
= -0.009, p = 0.07). In these models, educational level was
significantly and positively associated with component 3,
only (B = 0.40, p = 0.002).
The above mentioned multiple regression models were
repeated including further the variable describing the type
of current doctor during outpatient treatment (general
practitioner, private psychiatrist, community psychiatry
doctor, hospital doctor, other doctor). There were no sig-
nificant associations between any of the scores and type of
doctor (p > 0.05).
4. Discussion
The most consistent finding in the study was that among
patients discharged from hospital with depressive or bipo-
lar disorders, older patients consistently had a more nega-
tive view on the doctor-patient relationship (Component
1), a more negative view on mood stabilizers (Compo-
nent 2) and more non-correct views on the effect of mood
stabilizers (Component 3). Further, adjusting for differ-
ences in age, there were no differences between patients
with depressive and patients with bipolar disorder in any
component. There was no difference in the attitudes and
beliefs according to the number of psychiatric hospitalisa-
tions or according to the type of the current doctor (gen-
eral practitioner, private psychiatrist, community
psychiatry doctor, hospital doctor, other doctor).
Although the major proportion of patients with depres-
sive disorder and as well as with bipolar disorder agreed
on the diagnosis and the choice and effect of pharmaco-
logical treatment and the majority felt content with their
doctor and with information a large proportion of the
patients had non-correct views on the effect of mood sta-
bilizers (Component 3 and 4 (Preserved autonomy)). A
total of 77.4 % of patients believed that as long as you are
taking a mood stabilizer you do not really know if they are
actually necessary and 36 to 50 % that you can become
addicted or that mood stabilizers can alter your personal-
ity. It is most probably that such attitudes may result in
reluctance to take mood stabilizers in the long run.
We included questions on reasons for discontinuing treat-
ment but to few patients answered these questions. It is
well known that direct questions on reasons for stopping
treatment is flawed by a low response rate and by low
validity of the answers. Thus, there is no single valid way
to measure non-adherence [17]. Questionnaires on atti-
tudes and beliefs concerning illness and treatment such as
the ADCQ and the MSCQ may be less provocative for
patients and with a higher response rate.
We have previously reported on finding on attitudes and
beliefs on antidepressants among the larger population of
patients who received antidepressants [18]. Thus, among
the 493 patients who participated in the survey, 422
reported that they previously or currently were in treat-
ment with an antidepressant (and these patients fulfilled
the ADCQ, [18]) and 256 that they previously or currently
were in treatment with a mood stabilizer (and these
patients fulfilled the MSCQ). The main proportion (88
%) of patients who previously or currently were in treat-
ment with a mood stabilizer had at one point in time
received an antidepressant and these patients fulfilled
both questionnaires. The findings on attitudes and beliefs
Table 3: Age at first contact, gender, number of admissions and type of disorder (depressive or bipolar disorder) in relation to the 









Preserved Autonomy: dosing 
of mood stabilizers 
Component 4
B (95 % CI) B (95 % CI) B (95 % CI) B (95 % CI)
Age -0.010 (-0.02 – 0.004)** -0.010 (-0.02 – 0.005)** -0.015 (-0.02 – 0.005)** -0.003 (-0.009–0.002)
Female gender -0.19 (-0.41–0.03) -0.01 (-0.23–0.20) 0.14 (-0.11–0.38) -0.03 (-0.11–0.16)
Number of admissions -0.006 (-0.076–0.064) -0.008 (-0.08–0.06) 0.003 (-0.06–0.08) 0.007 (-0.04–0.05)
Depressive versus bipolar disorder -0.18 (-0.41–0.04) -0.20 (-0.42–0.02) 0.02 (-0.22–0.26) -0.03 (-0.17–0.10)
* P ≤ 0.05 ** P < 0.01
All variables were included at the same time in the multiple regression models.Page 5 of 7
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ings on attitudes and beliefs on antidepressants. It seems
as patients who have negative attitudes toward mood sta-
bilizers also have negative attitudes toward antidepres-
sants as well, indicating a negative attitude toward
medication in general.
It should be noted that patients who participated in the
present study had had contact to the psychiatric health
care system all over Denmark representing not only spe-
cialist university centres but also rural psychiatric hospi-
tals, wards and centres.
Our findings are surprisingly similar to the results in a
study by Schaub et al. who included a relatively small
sample of patients (31 patients with depressive disorder
and 74 with bipolar disorder) from a specialized lithium
clinic [12]. In this study, patient's knowledge on lithium
treatment correlated negatively with age, whereas sex,
diagnosis and duration of treatment were unrelated to
knowledge. The MSQC has a broader scope than focusing
on knowledge of medication only, and further age was
consistent related to a more negative view on the diagno-
sis and on the doctor-patient relationship. The relation to
age is further in accordance with results from studies of
the general population [19,20]: the elderly had less correct
knowledge on mental illnesses and depression and were
more critical toward diagnosis and treatment. However, as
stated by Schaub et al. [12] associations about treatment-
related knowledge have not often been examined for-
mally in psychiatric settings, nor in settings of somatic dis-
eases [21]. As mood stabilizers often are prescribed for
many years and as elderly patients may present with cog-
nitive dysfunction and somatic co-morbidity, lack of
knowledge and a critical attitude toward diagnosis and
treatment may add to deteriorate the prognosis even
more. Such findings are consistent with the results from
an ongoing pharmacoepidemiological study from our
group showing that adherence to lithium is poor espe-
cially among patients aged 60 or more [22]. All together
these findings are consistent with the findings in some
studies that older patients with bipolar disorder may
present more often with mixed episodes and have a lower
treatment response [23] and a higher risk of recurrence
[24].
Although seldom investigated, prior studies have not
found gender differences in knowledge of treatment [12].
Similarly in the present study, no gender differences were
found in attitudes toward diagnosis or treatment.
In the study by Schaub et al from a specialized lithium
clinic, patients with depressive disorder had a lower
knowledge about lithium treatment than patients with
bipolar disorder [12]. In the present study there was no
difference among patients with these disorders. ICD-10
does not discriminate between bipolar disorder type 1
and 2 as both are categorised as bipolar disorder [15]. We
cannot exclude that some patients may have been misclas-
sified as suffering from depressive disorder instead of
bipolar disorder and that this may have diluted possible
differences between the two illnesses.
We did not find any associations between scores on
MSQC and the number of psychiatric hospitalisations. We
are not aware of any other study besides the study by
Schaub et al [12] that has investigated the relation
between course of illness and attitudes and beliefs on ill-
ness and treatment. To avoid bias such studies have to be
conducted prospectively as discussed in the following sec-
tion on caveats of the present study.
4.1. Caveats of the study
General pitfalls in relation to the study design has been
reported elsewhere [18]. In short, overall, approximately
50 % of patients answered the letter, a rate that equals the
response rate in satisfaction questionnaire surveys in gen-
eral [25]. Contrary to most studies on satisfaction con-
ducted by mail we did not exclude very ill patients,
patients who had been involuntary hospitalised, patients
with dementia, the illiterate or emigrants, etc [25]. The
questionnaires were mailed to all patients who gained
contact to psychiatric hospital health care as described in
the inclusion criteria. Patients who responded to the
MSQC had a rather positive view upon illness and their
doctor-patient relationship so we cannot exclude that
patients with a more negative attitude has responded in a
less degree. However, we do not believe that this has
caused major bias in the revealed associations between
attitudes/beliefs and socio-demographic/clinical variables
as only slightly more women responded to the question-
naires and as the responses did not vary according to age,
type of disorder or number of hospitalisations (Table 1).
Although there was no difference in the response rate
among patients with a poor versus better course of illness
as indicated by many versus few hospitalisations we can-
not exclude that the prevalence of other indicators of a
poor outcome, such as co-morbidity with substance abuse
or personality disorders, was higher among non-respond-
ers.
The diagnoses were made by psychiatrist all over Den-
mark according to ICD-10 and was not standardised for
research purposes.
We do not have information on the number of affective
episodes patients have experienced. It is well known that
patients are hospitalised for the most severe depressive
episodes only (mainly with somatic or psychotic symp-
toms) and for moderate to severe manic episodes [26]. WePage 6 of 7
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cannot exclude that there exist an association between the
number of episodes or the duration of the illnesses and
attitudes and beliefs according on depression and mood
stabilizers. However, using the number of psychiatric hos-
pitalisations as a measure of the course of illness we did
not find that patients with a more severe course of illness
(i.e., more hospitalisations) had a more negative attitudes
and beliefs. This negative finding may be due to bias as
those patients who seek hospitalisations many times also
may constitute the proportion of patients with severe ill-
ness with a more positive view upon treatment and the
health care system.
Thus, the study presented cross sectional data. We plan to
conduct a follow-up study analysing whether these cross
sectional data on attitudes and beliefs on mood stabilizers
predict the risk of hospitalisation in the future.
Finally, the study does not include data on adherence to
treatment. Future studies may investigate whether the
MSQC is predictive of compliance with mood stabilizers.
In conclusion, the study showed that there seems to be a
lack of knowledge and a critical attitude toward diagnosis
and treatment in patients treated with mood stabilizers
and especially among the elderly patients. This may add to
deteriorate the prognosis of depressive and bipolar disor-
ders. There is a need to further investigate whether this is
actually the case.
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